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 Abstract 
 The use of cancer-related therapies in cancer patients hospitalized at the end of life has in-
creased in many countries over time. Given the scarcity of published Swiss data, the objective 
of this study was to evaluate the influence of hospital type and other factors on the delivery 
of health care during the last month before death. Claims data were used to assess health care 
utilization of cancer patients (identified by cancer registry data of four participating Swiss 
cantons) who deceased between 2006 and 2008. Primary endpoints were delivery of cancer-
related therapies during the last 30 days before death. Multivariate logistic regression as-
sessed the explanatory value of hospital type, patient and geographic characteristics. Of 3,809 
identified cancer patients in the claims database, 2,086 patients dying from cancer were hos-
pitalized during the last 30 days before death, generating 2,262 inpatient episodes. Anticancer 
drug therapy was given in 22.2% and radiotherapy in 11.7% of episodes. Besides age and can-
cer type, the canton of residence and hospital type showed independent, statistically signifi-
cant associations with intensity of care, which was highest in university hospitals. These results 
should initiate a discussion among oncologists in Switzerland and may question the compli-
ance with standard of care guidelines for terminal cancer patients.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Delivery of health care at the end of life of cancer patients has gained increasing attention 
during the last decade  [1–5] . While the intensity of care in general seems to have increased 
over time  [6–8] , the appropriateness and quality of delivered care is increasingly discussed 
 [9, 10] . Furthermore, the results of studies show that care at the end of life is not uniformly 
delivered to all patients but is influenced by several demographic and geographic factors 
 [11–13] . Why and to what degree these inequalities exist or if they should be a matter of 
concern is unclear. Demand- or supply-driven over- or undertreatment are difficult to distin-
guish in retrospective studies and prospective studies on end-of-life care are difficult to 
perform. Still, retrospective nationwide studies on how cancer patients are treated at the end 
of life may uncover existing disparities and can deliver important information to the oncol-
ogist community as well as policy makers in order to discuss the prevailing practice or effects 
of modification of such a practice.
 The first large-scale study on end-of-life cancer care in four Swiss cantons was performed 
in 2011, using health insurance data for the delivery of care information (for patients deceased 
between 2006 and 2008) and cancer registry data to identify cancer patients  [14].  This study 
revealed significant differences in the intensity of care during the last 30 days before death, 
between patients with different insurance types as well as between patients living in different 
cantons. One of the limitations of the primary analysis was that for some of the included 
patients (those without hospitalization during the last month before death) no information 
on the cause of death was available. This might have led to a dilution of the results, caused by 
patients who did not die from cancer. In addition, in this first analysis the effect of the type of 
treating hospital was not included. Therefore, we decided to perform a more in-depth analysis 
on the cohort of patients who were hospitalized during the last 30 days before death and had 
a known cancer-related cause of death. This analysis concentrates on the estimation of the 
effect different hospital types might have on the intensity of care given at the end of life.
 Patients and Methods 
 A detailed description of the study methodology is given in a previous publication  [14] .
 Study Population 
 The original retrospective study included patients aged 20 years or older at the time of cancer diagnosis, 
who died between 2006 and 2008, lived in one of the participating Swiss cantons, and had been customers 
of the Helsana Group insurance company for at least 1 year before death. In short, 3,809 patients from four 
cantons [Basel-Stadt/Basel-Landschaft (BS/BL; language German, one university hospital), Ticino (TI; 
language Italian, no university hospital), Valais (VS; language German and French, no university hospital) and 
Zurich (ZH; language German, one university hospital); Swissmap, 2001] were identified as being eligible and 
were included in the original study. During the last 30 days before death, 2,608 (68.5%) of these patients 
were hospitalized in 49 different acute care hospitals. For 2,494 (96%) of these patients, inpatient infor-
mation was available and for 2,086 (83.6%), hospitalization was cancer-related [defined as patients who had 
a primary admission diagnosis indicative of cancer, and/or had cancer-related symptom(s) or diseases, or 
had a non-cancer-related reason for admission but suffered from ongoing active cancer as described in the 
patient history]. The following analysis is based on these 2,086 patients. As some of the patients were hospi-
talized more than once in different hospitals, the study was based on the total episodes of hospitalizations 
(n = 2,262).
 In- and Outpatient Delivered Care Information 
 Swiss claims data relating to inpatient episodes do not contain full details on the treatments and diag-
nostic procedures performed. Therefore, this information was collected from the patient records in the 
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hospitals. Information on outpatient care is available in detail in the Helsana claim database. Anticancer drug 
therapy (ACDT) is defined by the anatomical therapeutic chemical codes (online suppl. table S1; for all online 
suppl. material, see www.karger.com/doi/10.1159/000367629), and radiotherapy (RT) by TARMED reim-
bursement codes or as described in the patient record. TARMED is the Swiss tariff system for medical services 
provided to outpatients (Tarmed, 2006–2008).
 Outcomes and Covariates 
 The primary endpoints of this study were indicators of the intensity of care delivered to cancer patients 
in the last 30 days before death, defined as the administration of ACDT, RT or ACDT and/or RT (D ao RT). A 
distinction was made between purely inpatient and in- and/or outpatient (ANY) administered therapies as 
many therapies are delivered in the hospital but in an ambulatory setting. These endpoints were set in 
relation to the potential explanatory variables as described below.
 The following patient characteristics were collected: age at death, gender, cancer type (colon, hemato-
logic, lung, breast, prostate, and all others combined), and hospital supplemental insurance (HSI) type (no 
HSI = basic obligatory health insurance hospitalization only on the general ward in predefined hospitals 
within the canton of residence, ECO = basic HSI hospitalization on the general ward with free choice of 
hospital all over Switzerland, SP + P = semiprivate or private hospitalization in a double or single bedroom 
and free choice of hospital all over Switzerland).
 The hospitals were characterized according to different levels as follows: level 1 university hospitals 
(L1 US), level 2 central service hospitals (L2 CSH), level 3 large regional service hospitals (L3 RSH-L), level 4 
medium regional service hospitals (L4 RSH-M), and level 5 small regional service hospitals including some 
small specialized hospitals (L5 RSH-S). These levels are (except for L1 US) defined by the number of treated 
inpatients per year  [15] .
 Statistical Analysis 
 The main statistical analysis follows the scheme described in the original study. In short, endpoints were 
described using frequencies and percentages in the case of categorical variables. Age was given as mean, 
median and standard deviation. The effect of age on the endpoints was evaluated, and for nonlinear associa-
tions age was divided into splines based on the segmented polynomial approach  [16, 17] . Multivariate logistic 
regressions were performed using a stepwise method to select statistically significant explanatory variables. 
Parameter estimates and odds ratios (ORs) were calculated including the Wald 95% confidence intervals 
(95% CI); p values were two-sided and considered significantly significant if <0.05. Given the explorative 
nature of this study, there was no adjustment for multiple testing. To test for effect dependency of the results 
for those patients with more than one hospitalization a model was evaluated including generalized esti-
mating equation-based robust standard errors allowing for clustering by patient. All statistical analyses were 
performed with SAS ® , version 9.3.
 This study was approved by the ethics committees of the cantons BS/BL, TI, VS and ZH and the expert 
committee for data protection and professional confidentiality in medical research of the federal office of 
public health.
 Results 
 Of the 2,086 patients included in this study, 7.2% (n = 150) were hospitalized in two 
different and 0.6% (n = 13) in 3 different hospitals during the last 30 days before death. Eighty 
percent of the patients died while hospitalized.
 Overall most of the hospitalizations were in L2 CSH followed by L4 RSH-M ( table 1 ). Except 
for L5 RSH-S, in all other hospital types more male than female patients were hospitalized. The 
distribution of the cancer types among the different hospital types was similar for levels 1–4. 
Only L5 RSH-S hospitals differed with fewer lung cancer patients and more breast cancer 
patients. The HSI type was quite uniformly distributed among the hospital types, with the 
highest proportion of patients without an HSI in the university hospitals. The distribution of 
hospital types by canton of residence reflects the available hospital types in the four cantons: 
VS and TI do not have a university hospital, and VS does not have L3 RSH-M hospitals. The 
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mean age at death was similar among the hospital types, except for L1 US where the age at 
death was significantly lower (levels 2–5, mean age 73 years; L1 US, mean age 67 years).
 Of all episodes, 10.2% received inpatient ACDT and 22.2% ANY ACDT within the last 30 
days before death ( table 2 ;  fig. 1 ). ACDT (inpatient and ANY) was mostly given to patients 
with hematologic cancers (inpatient 17.8%, ANY 29.6%), having an SP + P HSI (inpatient 
12.3%, ANY 26.7%), living in TI (inpatient 13.2%, ANY 26.9%) or being hospitalized in 
university hospitals (inpatient 18.5%, ANY 33.4%). Inpatient RT was given in 5.3% and ANY 
in 11.7% of cases. Lung cancer patients received most RT (inpatient 7.8%, ANY 16.8%). The 
HSI type hardly influenced the proportion of cases receiving RT. In the two cantons with a 
university hospital (BS/BL and ZH), RT was given more frequently (inpatient and ANY) than 
in the two cantons without such a hospital type. Patients in university hospitals received most 
RT (inpatient 12.5%, ANY 18.5%). Inpatient D ao RT was given in 14.7% and ANY in 30.9% of 
the cases. Lung cancer patients received most D ao RT (inpatient 20.2%, ANY 38.3%), as well 
as patients with an SP + P HSI (inpatient 16.4%, ANY 34.4%), patients living in TI (inpatient 
16.3%, ANY 32.6%) or patients being treated in L1 US hospitals (inpatient 28.6%, ANY 46.3%).
 As already observed in the original study, receiving ACDT or RT was strongly age 
dependent. Until the death age of 65 years, a weak linear relationship between age and the 
probability of receiving ACDT was observed, followed by a clear linear decrease in therapy 
frequency after the death age of 65 years. A similar two-phase trend was observed for RT with 
a bend at the death age of 75 years ( fig. 2 ). For this reason, multivariate logistic regression 
was performed using the spline methodology for age.
 Table 1.  Descriptive statistics: demographic and geographic information by hospital type (in %) 
All
(n = 2,262)
L1 US
(n = 287)
L2 CSH
(n = 865)
L3 RSH-L
(n = 434)
L4 RSH-M
(n = 468)
L5 RSH-S
(n = 208)
Overall 12.7 38.2 19.2 20.7 9.2
Gender
Male 54.6 55.1 57.8 52.5 56.0 41.3
Female 45.4 44.9 42.2 47.7 44.0 58.6
Cancer diagnosis
Colon 7.2 4.2 7.4 9.4 7.5 4.8
Hematologic 7.5 10.1 6.1 8.1 9.2 4.3
Lung 18.1 22.6 18.6 17.5 16.0 4.8
Mammary 8.4 10.1 7.6 8.3 7.3 12.5
Prostate 8.1 7.0 8.7 8.7 8.1 6.3
Other 50.7 46.0 51.6 48.0 51.9 56.3
HSI status
None 28.7 34.8 29.4 29.7 23.3 27.4
ECO 39.6 33.5 42.1 41.9 38.0 36.1
SP + P 31.7 31.7 28.5 28.3 38.7 36.5
Canton of residence
BS/BL 11.4 21.3 11.8 10.8 0.2 22.1
TI 26.8 0.3 28.8 12.9 51.7 28.4
VS 6.2 0 6.6 0 17.5 1.0
ZH 55.6 78.4 52.8 76.3 30.6 48.5
Age
Mean
Median
Standard deviation
72.6
74
11.78
67.3
68
12.58
73.1
74
11.57
73.3
75
11.75
73.6
75
11.13
73.5
75
11.23
 Number of hospitalizations = 2,262; number of patients = 2,086. 
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 For the multivariate logistic regression, only a minimal impact of clustering of inpatient 
episodes within patients with more than one episode (7.81% of all patients) on standard 
errors was observed. Therefore, clustering was ignored in the final models.
 The multivariate logistic regression for receiving inpatient ACDT showed significant 
effects for the variables (online suppl. table S2;  fig. 3 ) age (decrease with increasing age), 
cancer type (prostate vs. lung cancer: OR = 0.39, 95% CI = 0.17–0.89), canton of residence (TI 
vs. ZH: OR = 1.93, 95% CI = 1.34–2.78), and hospital type (compared to central service 
hospitals: university hospital: OR = 2.06, 95% CI = 1.13–3.74; medium regional hospitals: 
OR = 1.66, 95% CI = 1.08–2.56; small regional hospitals: OR = 0.39, 95% CI = 0.162–0.933). 
There was a significant interaction between hospital type and age indicating that the decrease 
in receiving ACDT with increasing age was significantly less prominent in the medium regional 
hospital type.
 Considering the different cancer types, receiving ANY ACDT showed different results 
compared to receiving only inpatient ACDT, with colon (OR = 1.89, 95% CI = 1.14–3.14) and 
hematologic cancer patients (OR = 1.93, 95% CI = 1.19–3.15) having higher odds of receiving 
ANY ACDT than lung cancer patients ( fig. 3 ). Patients living in the canton TI again showed 
significantly higher odds of receiving ANY ACDT (OR = 1.69, 95% CI = 1.30–2.21), as well as 
patients treated in university hospitals (OR = 1.67, 95% CI = 1.21–2.32). Patients treated in 
small regional hospitals once more had much lower odds of receiving ANY ACDT (OR = 0.38, 
95% CI = 0.23–0.63). In addition, patients with an SP + P HSI had a higher probability of 
receiving ANY ACDT (OR = 1.45, 95% CI = 1.10–1.91). A significant interaction between age 
and cancer type was observed demonstrating that with increasing age the differences between 
the cancer types became more prominent than at a younger age.
 Inpatient and ANY RT was only significantly influenced by age and hospital type for 
patients hospitalized in smaller hospitals (levels 3–5) having lower odds of receiving RT (no 
inpatient RT in regional medium-sized hospitals;  fig. 3 ).
 Receiving inpatient or ANY D ao RT was significantly influenced by age, cancer type, canton 
of residence and hospital type ( fig. 3 ). Patients living in TI had significantly higher odds of 
receiving D ao RT during the last 30 days before death (inpatient: OR = 1.61, 95% CI = 1.18–
2.19; ANY: OR = 1.38, 95% CI = 1.09–1.75). In addition, patients treated in university hospitals 
had significantly higher odds of receiving D ao RT (inpatient: OR = 1.83, 95% CI = 1.30–2.59; 
ANY: OR = 1.45, 95% CI = 1.08–1.94), while the odds decreased for the smaller regional 
hospital types (levels 3–5).
 Table 2. Descriptive statistics: delivered cancer care
Inpatient ACDT ANY ACDT Inpatient RT ANY RT Inpatient DaoRT ANY DaoRT
All (n = 2,262) 10.2 (8.9 – 11.4) 22.2 (20.5 – 24.0) 5.2 (4.3 – 6.1) 11.7 (10.3 – 13.0) 14.7 (13.2 – 16.1) 30.9 (29.0 – 32.8)
Gender
Male (n = 1,234) 9.7 (8.1 – 11.4) 22.4 (20.1 – 24.8) 5.4 (4.2 – 6.7) 13.0 (11.1 – 14.8) 14.3 (12.4 – 16.3) 32.1 (29.5 – 34.7)
Female (n = 1,028) 10.7 (8.8 – 12.6) 22.0 (19.5 – 24.5) 5.0 (3.6 – 6.3) 10.1 (8.3 – 12.0) 15.1 (12.9 – 17.3) 29.4 (26.6 – 32.2)
Cancer diagnosis
Colon (n = 162) 9.3 (4.8 – 13.7) 25.9 (19.2 – 32.7) 6.2 (2.5 – 9.9) 9.3 (4.8 – 13.7) 13.6 (8.3 – 18.9) 32.1 (24.9 – 39.3)
Hematologic (n = 169) 17.8 (12.0 – 23.5) 29.6 (22.7 – 36.5) 3.0 (0.4 – 5.5) 10.7 (6.0 – 15.3) 18.9 (13.0 – 24.8) 34.3 (27.2 – 41.5)
Lung (n = 410) 13.2 (9.9 – 16.4) 24.6 (20.5 – 28.8) 7.8 (5.2 – 10.4) 16.8 (13.2 – 20.5) 20.2 (16.4 – 24.1) 38.3 (33.6 – 43.0)
Mammary (n = 191) 14.7 (9.6 – 19.7) 28.3 (21.9 – 34.7) 4.2 (1.3 – 7.0) 9.9 (5.7 – 14.2) 17.8 (12.4 – 23.2) 35.1 (28.3 – 41.9)
Prostate (n = 184) 3.8 (1.0 – 6.6) 15.2 (10.0 – 20.4) 6.0 (2.6 – 9.4) 12.5 (7.7 – 17.3) 9.9 (5.5 – 14.1) 26.6 (20.2 – 33.0)
Other (n = 1,146) 8.4 (6.8 – 10.0) 19.9 (17.6 – 22.2) 4.5 (3.3 – 5.7) 10.5 (8.7 – 12.2) 12.5 (10.6 – 14.4) 27.5 (24.9 – 30.1)
Figures are percentages with 95% CIs in parentheses. 
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 Fig. 1. Descriptive statistics for cancer therapies by HSI status, canton of residence and hospital type.  
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 Discussion 
 Overall the frequency of delivered in- and outpatient cancer therapies (30.9% of the 
episodes) in four Swiss cantons was similar to the values found in other studies  [18, 19] and 
was 10% higher than seen in the total cohort as described in the original study  [14] . In 
addition, we found that within Switzerland the probability of receiving ACDT, or ACDT and/
or RT (inpatient and ANY), during the last 30 days before death not only differed by cancer 
type and age, but also between treating hospital types and canton of residence. Different 
treatment intensities can be expected for different cancer types  [20] or they might decrease 
with age. However, significant differences in the intensity of care between hospitals and 
cantons may hint at under- or overtreatment issues. Especially, the significantly higher odds 
of receiving cancer-related cancer care in a canton without a university hospital should 
trigger discussions.
 In the original study, the HSI status played a significant role in the treatment received 
(in- and/or outpatient ACDT as well as ACDT and/or RT). Yet, in this cohort of patients with 
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a known cause of death, this factor only plays a significant role for the combined in- and 
outpatient ACDT outcome, where patients with an SP + P HSI show a significantly higher 
probability of receiving such a therapy. For the solely inpatient outcomes, the insurance 
status did not have a significant effect. One reason might be that the influence of the hospital 
type masks the effect of the insurance status, as more patients with an SP + P HSI are hospi-
talized in medium and small regional hospital types. Overall these findings are somewhat 
similar to those reported by Keating et al.  [21] , who showed that patients treated in a private 
setting had a higher probability of receiving ACDT during the last 2 weeks before death.
 The effect of the hospital type on the intensity of end-of-life care is understudied and the 
existing literature is conflicting. Whereas some studies found an influence of the hospital type 
on the delivered care at the end of life  [22, 23] , others did not show such effects  [21, 24] . In 
our study, we showed that being hospitalized in 2 out of a total of 5 university hospitals in 
Switzerland significantly increases the odds of receiving any kind of cancer-related therapies 
(inpatient and ANY). A second peculiarity is that patients hospitalized in medium-sized 
regional hospitals show second highest odds of receiving inpatient ACDT. As none of these 
hospitals seems to provide RT, one might ask whether the absence of RT facilities is compen-
sated by delivering more ACDT.
 This study has some limitations. One of them is that only cancer patients who had been 
hospitalized during the last 30 days before death were included in the analysis. Patients not 
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 Fig. 3. Multivariate logistic regression: ORs for significant explorative variables for in- and outpatient cancer 
therapies. Mamm. = Mammary; hematol. = hematologic. 
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hospitalized during the last month before death (approx. ±30% of the original cohort) could 
not be explicitly identified as dying from cancer because of missing exclusive cause of death 
information. Therefore, the observed numbers might be too high as they only refer to patients 
hospitalized during the last 30 days before death. Not hospitalized cancer patients may not 
have received any cancer-related therapy during this period. Furthermore, selection bias due 
to a limited number of cantons being included as well as the use of data from only one 
insurance company may limit conclusions. Although cancer-related outpatient therapies are 
mostly initiated in a hospital and given in an ambulatory setting, we were not able to identify 
whether the received outpatient therapies were directly related to/initiated by the hospital 
in which the patients stayed. Another uncertainty is whether or not referral to the different 
hospital types (therefore, expected treatment) is related to the clinical condition and personal 
preferences of the patients.
 Research on end-of-life cancer care, especially in Europe, has only emerged during the 
last two decades and still receives only minimal financial support  [25] . The importance of 
such research is evident, as disparities between countries, within countries and among 
different patient populations do matter on many levels such as quality of care issues  [26–31] , 
economical aspects  [32–34] or shifts in the delivery of care over time  [35] .
 Conclusion 
 As shown in this study, for Swiss cancer patients hospitalized during the last 30 days 
before death, the probability of receiving cancer-related therapies depends on age, cancer 
type, canton of residence and hospital type. These results should serve as a basis for discus-
sions among oncologists in Switzerland and may question the compliance with standard of 
care guidelines for terminal cancer patients. Furthermore, the results of this study may serve 
as a bench mark. In 2012, the Swiss health care system changed to the Swiss DRGs. The effect 
of this change on the delivery of health care can be investigated in the near future comparing 
pre- and post-2012 data.
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